Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
MI-192 (MI192) is a novel and potent inhibitor of histone deacetylases (HDACs) with anticaner and neuroprotective activities. It exhibits selectivity for inhibiting HDAC2 (IC50 = 30 nM) and HDAC3 (IC50 = 16 nM) over HDAC1, 4, 6, 7, and 8 (IC50s = 4.8, 5, >10, 4.1, and >10 μM, respectively).
ln Vitro |
MI-192 (0.15-1 μM; 72 h) promotes apoptosis in acute myeloid leukaemic cell lines U937, HL60, and Kasumi-1, which leads to differentiation and is cytotoxic[1].
|
---|---|
ln Vivo |
When photothrombotic stroke is induced in mice, MI-192 (40 mg/kg; ip; once daily; for three days) exhibits neuroprotective effects in the brain[2].
|
Cell Assay |
Apoptosis Analysis[1]
Cell Types: HL60 and Kasumi- 1 cells Tested Concentrations: 150 nM, 300 nM, 500 nM, 1 μM Incubation Duration: 72 h Experimental Results: Induced a substantial degree of apoptosis in both HL60 and Kasumi-1 cells. |
Animal Protocol |
Animal/Disease Models: Adult male outbred mice CD-1 (20-25 g ) with photothrombotic stroke (PTS)[2]
Doses: 40 mg/kg Route of Administration: ip; one time/day; for 3 days Experimental Results: decreased the volume of the PTS-induced infarction core in the mouse brain, partly restored the functional symmetry in the forelimb use, diminished the level of PTS-induced apoptosis and acetylation of α-tubulin characteristic for stable microtubules, and increased the expression of GAP-43 in the cerebral cortex of the damaged hemisphere. |
References |
|
Molecular Formula |
C24H21N3O2
|
---|---|
Molecular Weight |
383.45
|
Exact Mass |
383.163
|
CAS # |
1415340-63-4
|
PubChem CID |
56965342
|
Appearance |
White to off-white solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
565.0±50.0 °C at 760 mmHg
|
Flash Point |
295.5±30.1 °C
|
Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
Index of Refraction |
1.693
|
LogP |
2.19
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
29
|
Complexity |
626
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
GTLTXEIKQVWSRF-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C24H21N3O2/c1-16-14-27(24(29)20-7-3-2-6-19(16)20)15-17-10-12-18(13-11-17)23(28)26-22-9-5-4-8-21(22)25/h2-13H,1,14-15,25H2,(H,26,28)
|
Chemical Name |
N-(2-aminophenyl)-4-[(4-methylidene-1-oxo-3H-isoquinolin-2-yl)methyl]benzamide
|
Synonyms |
MI192 MI 192 MI-192
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6079 mL | 13.0395 mL | 26.0790 mL | |
5 mM | 0.5216 mL | 2.6079 mL | 5.2158 mL | |
10 mM | 0.2608 mL | 1.3040 mL | 2.6079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.